This is a StreetInsider.com Premium Only Page

Aptevo Therapeutics (APVO) – Trader Talk

Dec 12, 2022 07:58 AM Aptevo Therapeutics (APVO) Climbs 95% After Announcing 100% Clinical Benefit Rate Achieved in Phase 1b Trial Evaluating APVO436 in Combination with Venetoclax and Azacitidine

Nov 23, 2021 01:06 PM Aptevo Therapeutics (APVO) halted again on volatility as shares surge 172%

Nov 23, 2021 12:55 PM

Nov 23, 2021 08:13 AM

Nov 9, 2020 06:13 AM

Jun 12, 2017 04:06 PM